Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) EPS (Weighted Average and Diluted) (2021 - 2026)

Syndax Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.48 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 51.02% year-over-year to -$0.48; the TTM value through Mar 2026 reached -$2.79, up 27.53%, while the annual FY2025 figure was -$3.29, 11.56% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.48 at Syndax Pharmaceuticals, up from -$0.78 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.48 in Q1 2026 and troughed at -$1.09 in Q4 2024.
  • A 5-year average of -$0.76 and a median of -$0.73 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 133.7% in 2022 and later surged 51.02% in 2026.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.62 in 2022, then tumbled by 62.9% to -$1.01 in 2023, then dropped by 7.92% to -$1.09 in 2024, then grew by 28.44% to -$0.78 in 2025, then surged by 38.46% to -$0.48 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SNDX at -$0.48 in Q1 2026, -$0.78 in Q4 2025, and -$0.7 in Q3 2025.